scispace - formally typeset
Search or ask a question

Showing papers by "Natalie E. Dean published in 2019"

Journal Article•DOI•
Design of vaccine efficacy trials during public health emergencies

[...]

Natalie E. Dean1, Pierre Stéphane Gsell2, Ron Brookmeyer3, Victor De Gruttola4, Christl A. Donnelly5, Christl A. Donnelly6, M. Elizabeth Halloran7, M. Elizabeth Halloran8, Momodou Jasseh9, Martha Nason10, Ximena Riveros2, Conall H. Watson9, Ana Maria Henao-Restrepo2, Ira M. Longini1 •
University of Florida1, World Health Organization2, University of California, Los Angeles3, Harvard University4, University of Oxford5, Imperial College London6, University of Washington7, Fred Hutchinson Cancer Research Center8, University of London9, National Institutes of Health10
03 Jul 2019-Science Translational Medicine
TL;DR: The need for flexible and responsive vaccine trial designs to be used in public health emergencies is outlined, and recommendations for their use in this setting are summarized.
Abstract: Public health emergencies, such as an Ebola disease outbreak, provide a complex and challenging environment for the evaluation of candidate vaccines. Here, we outline the need for flexible and responsive vaccine trial designs to be used in public health emergencies, and we summarize recommendations for their use in this setting.

41 citations

Journal Article•DOI•
An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool.

[...]

Steven E. Bellan1, Rosalind M Eggo2, Pierre-Stéphane Gsell3, Adam J. Kucharski2, Natalie E. Dean4, Richard Donohue5, Matthew Zook5, W. John Edmunds2, Frank Odhiambo6, Ira M. Longini4, Marc Brisson7, Marc Brisson8, Barbara E. Mahon9, Ana Maria Henao-Restrepo3 •
University of Georgia1, University of London2, World Health Organization3, University of Florida4, University of Kentucky5, Kenya Medical Research Institute6, Laval University7, Imperial College London8, Centers for Disease Control and Prevention9
24 Jun 2019-Vaccine
TL;DR: InterVax-Tool (vaxeval.com) is a structured decision-support tool for trial design that helps vaccine efficacy trial design during outbreaks and emergencies include epidemiological, statistical, ethical, and logistical difficulties.

11 citations

Journal Article•DOI•
Re: "measurement of vaccine direct effects under the test-negative design".

[...]

Natalie E. Dean1•
University of Florida1
01 Apr 2019-American Journal of Epidemiology

11 citations

Journal Article•DOI•
Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods.

[...]

Gillian Hunt1, Johanna Ledwaba1, Monalisa Kalimashe1, Anna Salimo1, Siyabonga Cibane1, Beverly Singh1, Adrian Puren1, Natalie E. Dean2, Lynn Morris3, Lynn Morris1, Michael R. Jordan4 •
National Health Laboratory Service1, University of Florida2, University of the Witwatersrand3, Tufts University4
01 Jan 2019-Antiviral Therapy
TL;DR: These data provide national TDR estimates for South Africa in 2012 and indicate that levels of TDR were low to moderate for the NNRTI drug class and low for NRTIs and PIs in the population surveyed.
Abstract: BackgroundSentinel surveillance of transmitted HIV drug resistance (TDR) among recently infected populations within a country was recommended by the World Health Organization from 2004 to 2015.Meth...

4 citations